Regulatory Aspects of Continuous Pharmaceutical Manufacturing
-
Upload
ajaz-s-hussain-phd -
Category
Business
-
view
415 -
download
2
Transcript of Regulatory Aspects of Continuous Pharmaceutical Manufacturing
05/02/2023Ajaz S Hussain | Insight, Advice & Solutions LLC
1 Regulatory Aspects of Continuous Pharmaceutical ManufacturingDIGITAL PHARMA MANUFACTURING ROUNDTABLEKRONBERG, GERMANY, MARCH 17 2017
Ajaz Insights [email protected]
05/02/2023Ajaz S Hussain | Insight, Advice & Solutions LLC
2 A story about manufacturing two products, medicinal product and documented data, and a “little secret”
• Little Secret? Perhaps some of you may remember and recall the front page article in the Wall Street Journal dated 3 September 2003
• “The Pharmaceutical Industry Has a Little Secret”
• “Even as it invents futuristic new drugs, its manufacturing techniques lag far behind those of potato-chip and laundry soap makers.”
[Pharmaceutical] Industrial Revolutions: 1.0, 2.0, 3.0, and 4.0?
•Background: How did the journey begin in 2000 and progress until 2005? If you are interested please click on the video message from the past
• Pharmaceutical cGMPs for the 21st Century — A Risk-Based Approach
•Today we have an unprecedented juxtaposition of the main forces necessary for the US pharmaceutical manufacturing renaissance – we are at the Tipping Point05/02/2023
Ajaz S Hussain | Insight, Advice & Solutions LLC
3
05/02/2023Ajaz S Hussain | Insight, Advice & Solutions LLC
4 Hello, I am Dr. Ajaz S. Hussain.
I am passionate about making high pharmaceutical quality affordable to all.
• President, the National Institute for Pharmaceutical Technology & Education http://nipte.org/
• Ajaz S Hussain Insight, Advice & Solutions LLC http://www.ajazhussain.com/
• Professional practice related to development of complex generics, biosimilars, QbD, Real-Time-Release, Continuous Manufacturing & strengthening culture of pharmaceutical quality • Not-for-profit
• Advocacy of NIPTE Education & Research Programs• Advisor (pro bono) to the USP & C-SOPS; Programing for
Continuous Manufacturing• Commercial
• Advisor to several pharmaceutical, biopharmaceutical, software and consulting firms
• Advisor & shareholder, CONTINUUS Pharmaceuticals
Academia: Currently Adjunct Professor @ Long Island University; previously tenured faculty @ University of Cincinnati (1989-1994)
US FDA: CDER /OPS Deputy Director (2000-2005) and other positons (1995-2000); Lead PAT & Pharmaceutical Quality for the 21st Century Initiatives & related ICH efforts
Industry: Formerly President & CSO @ Wockhardt (USA, 6/2012 to 6/2013), CSO & VP @ Philip Morris International (Switzerland, 2009-2012), Global Head & VP @ Sandoz (USA & Germany, 2005-2009)
05/02/2023Ajaz S Hussain | Insight, Advice & Solutions LLC
5 Unprecedented juxtaposition – at the Tipping Point• In the 21st Century, Quality
entangled with Security• With rapid globalization, societies
are experiencing increasing level of fear/apprehension
• Quality – Clinical entanglement remains elusive while placebo/nocebo effects are increasing
• The progress in pharmaceutical technologies such as real-time controls and continuous manufacturing,
• legislative recognition of the need for efficient pharmaceutical manufacturing as in the 21st Century Cures Act, and
• President Trump’s focus on manufacturing in the USA.Increasing societal demand for higher assurance of pharmaceutical quality and lower
prices, historical regulatory opposition and uncertainty is turning to regulatory preference for PAT based real-time-controls, continuous manufacturing and digital manufacturing enablers – the Tipping Point!
05/02/2023Ajaz S Hussain | Insight, Advice & Solutions LLC
6
Late
199
0s’ (
Med
ical
Gas
: Ai
r Se
para
tion
Uni
ts)
2004
-200
5 Sa
nofi-
Aven
tis
Com
para
bilit
y Pr
otoc
ol
(FD
A Ap
prov
ed -
Not
Im
plem
ente
d)
2006
MSD
/Mer
ck
Seve
ral,
….o
ther
s (n
ew
drug
s); g
ener
ics
face
d O
GD
pus
h-ba
ck
ND
A 26
038;
Ork
ambi
®,
Vert
ex P
harm
aceu
tical
s.
25 Ju
ne 2
015
……
……
……
……
……
……
……
……
Po
st-
appr
oval
cha
nge:
ND
A 02
1976
Pre
zist
a® ,
Jans
sen.
12
Apri
l 201
6 (C
ontin
uous
man
ufac
turi
ng
with
RTR
T)
Opposition FDA Initiatives
Lessons Learned Progress
historical regulatory opposition and uncertainty is turning to regulatory preference for PAT based real-time-controls, continuous manufacturing and digital manufacturing enablers
Reg
ulat
ory
hete
roge
neit
yU
S-EU
-Jap
an-R
OW
CM
C R
evie
w V
s C
GM
P In
spec
tion
sC
ompe
ndia
l Tes
ting
O
ther
05/02/2023Ajaz S Hussain | Insight, Advice & Solutions LLC
7 The consequence of the little secret is now being understood more broadly
http://www.fda.gov/ohrms/dockets/ac/02/briefing/3841B1_05_PFIZER.PDF ; FDA Science Board 16 November 2001
The “little secret” in (solid dosage) manufacturing•Certificate of Analysis : Uncertainty in solid-state material attributes•Research laboratory measurement systems such as dissolution : Life-cycle stability and reproducibility in QC?•Fixed equipment and process parameters: Committed in submissions, difficult to change post approval; why bother finding the real cause? •Uncertainty in the stability and capability of measurements and manufacturing process: Raises questions on adequacy of sampling and obstructs risk-based decisions•Globalization – variable empowerment/oversight: “FDA Approved” and “Validated”; frames the mindset and ease of rationalization - cheating by design & breaches in data integrity
05/02/2023Ajaz S Hussain | Insight, Advice & Solutions LLC
8
If you keep your head in the sand, you don't know where the kick's coming from. Herbie Mann
05/02/2023Ajaz S Hussain | Insight, Advice & Solutions LLC
9 Where there is a will there is a way!
05/02/2023Ajaz S Hussain | Insight, Advice & Solutions LLC
10 NDA 26038; Orkambi®, Vertex Pharmaceuticals 25 June 2015
From: Martin Warman, Kelly Swinney and Justin Pritchard. PAT for In Process Control (IPC) and Real Time Release Testing (RTRT) in Continuous Manufacturing. 7th Pharmaceutical Technology Conference on Continuous Manufacturing, Japan (December 2015)
Angle of Repose Tipping Point
05/02/2023Ajaz S Hussain | Insight, Advice & Solutions LLC
11 Two illustrative examples (small molecules)• FDA Awards $4.9 Million to Rutgers-
Led C-SOPS• FDA invitation to prepare and
submit a proposal for an "FDA guidance in Continuous Manufacturing“
• FDA Awards $4.4 Million to CONTINUUS Pharmaceuticals, Inc.• “Advancement of Integrated
Continuous Manufacturing (ICM) Unit Operations”; to develop a science and risk-approach on how drug quality can be monitored and improved through integrated continuous manufacturing (ICM).
C-SOPS GEA
MIT-Novartis: Continuus
The Manufacturing USA Strategy is rapidly evolving!
•Manufacturing USA consists of multiple linked Manufacturing Innovation Institutes• The National Institute for
Innovation in Manufacturing Biopharmaceuticals NIIMBL
•USP and C-SOPS Collaboration PCM
05/02/2023
Ajaz S Hussain | Insight, Advice & Solutions LLC
12
https://energycommerce.house.gov/
Credit: Ron Sachs/SIPA/Newscom
05/02/2023Ajaz S Hussain | Insight, Advice & Solutions LLC
13 Serious consideration needed for building your roadmap….
Remember Einstein’s challenge that we will never solve the problems tomorrow with the same order of consciousness we are using to create the problems of today!
05/02/2023Ajaz S Hussain | Insight, Advice & Solutions LLC
14
How?
• Pathfinder Option• You have the “PAT spirit”; you are not waiting for “guidance”
from regulators • You move now; engaging the regulators and taking them with
you on your visionary journey ; then you offer to train the regulators!
• Standard Option• You will wait for regulators to issue guidance • You get ready to move in about 3 years; you complete
implementation of Process Validation 2011 and QbD (Q8-11) –with a vigorous check for risk of breaches in the assurance of data integrity (and prevent suspicion of “are these data too good to be true?”)
• Emergency Option• Oh no! A bad inspection with the “dreaded” observations!• CAPA, process improvement & smart HPLC that says STOP to
“trial injections”
Leadership-drive and options
Industry 1.0
Industry 2.0
Industry 3.0
Industry 4.0
05/02/2023Ajaz S Hussain | Insight, Advice & Solutions LLC
15
What?
• Technology platforms• Manufacturing with controls [PAT-RTRT partial or full]
• API only, DF only, Integrated API & DF
• Rapid development, manufacturing with controls • PAT-RTRT with continuous manufacturing
• Other – human behavior motivation & monitoring , Big Data, pattern recognitions, etc.
• New (generic or brand) development Vs. Post Approval • OSD IR: BCS Class I, Direct Compression,….• OSD IR: BCS Class IV, Wet Granulation….• OSD MR: Extended Release• …….
• People & Organization Development , Partnerships & Collaboration
• Internal mindset shift and collaborations• Regulator communication and collaboration• Partnership & collaboration with Suppliers & Technical Experts• Collaboration with Academia (e.g., NIPTE)
You need to consider
Summary
•The little secret – swept under the rug? No more!
•Unprecedented juxtaposition – at the Tipping Point!
•Serious consideration needed for building your roadmap!
•Three options: Pathfinder, Standard or Emergency; what will you choose?
05/02/2023
Ajaz S Hussain | Insight, Advice & Solutions LLC
16